Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans.

The present study examined the role of the cytokine IL-6 in the regulation of fatty acid metabolism during exercise in humans. Six well-trained males completed three trials of 120 min of cycle ergometry at 70% peak O(2) consumption (Vo(2 peak); MOD) and 40% Vo(2 peak) with (LOW + IL-6) and without (LOW) infusion of recombinant human (rh)IL-6. The dose of rhIL-6 during LOW + IL-6 elicited IL-6 concentration similar to those during MOD but without altering the circulating hormonal milieu seen in MOD. Palmitate rate of appearance (R(a)), rate of disappearance (R(d)), and oxidation were measured by means of a constant infusion of [U-(13)C]palmitate (0.015 micromol.kg(-1).min(-1), prime NaHCO(3), 1 micromol/kg). Palmitate R(a), R(d), and oxidation were not affected by rhIL-6 infusion, remaining similar to LOW at all times. Palmitate R(a) and oxidation were significantly greater in the MOD trial (P < 0.05) compared with the LOW + IL-6 and LOW trials. Our data show that a low dose of rhIL-6, administered during low-intensity exercise without altering the hormonal milieu, does not alter fatty acid metabolism. These data suggest that the increase in fatty acid utilization seen during exercise at moderate compared with low intensity is not mediated via alterations in plasma IL-6.

[1]  M. Febbraio,et al.  Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. , 2005, American journal of physiology. Endocrinology and metabolism.

[2]  M. Febbraio,et al.  Suppressing lipolysis increases interleukin-6 at rest and during prolonged moderate-intensity exercise in humans. , 2004, Journal of applied physiology.

[3]  M. Febbraio,et al.  Skeletal myocytes are a source of interleukin‐6 mRNA expression and protein release during contraction: evidence of fiber type specificity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  C. Gravholt,et al.  Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[5]  B. Pedersen,et al.  Immunohistochemical detection of interleukin‐6 in human skeletal muscle fibers following exercise , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  M. Jensen Fate of fatty acids at rest and during exercise: regulatory mechanisms. , 2003, Acta physiologica Scandinavica.

[7]  M. Jensen Cytokine regulation of lipolysis in humans? , 2003, The Journal of clinical endocrinology and metabolism.

[8]  B. Saltin,et al.  Interleukin-6 stimulates lipolysis and fat oxidation in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  B. Saltin,et al.  Human Skeletal Muscle Fatty Acid and Glycerol Metabolism During Rest, Exercise and Recovery , 2002, The Journal of physiology.

[10]  M. Febbraio,et al.  Muscle‐derived interleukin‐6: mechanisms for activation and possible biological roles , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  J. Bülow,et al.  Metabolic effects of interleukin‐6 in human splanchnic and adipose tissue , 2002, The Journal of physiology.

[12]  J. Jansson,et al.  Intracerebroventricular interleukin-6 treatment decreases body fat in rats. , 2002, Biochemical and biophysical research communications.

[13]  C. Ohlsson,et al.  Interleukin-6-deficient mice develop mature-onset obesity , 2002, Nature Medicine.

[14]  Mitchell J. Anderson,et al.  Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running. , 2001, American journal of physiology. Cell physiology.

[15]  B. Saltin,et al.  Production of interleukin‐6 in contracting human skeletal muscles can account for the exercise‐induced increase in plasma interleukin‐6 , 2000, The Journal of physiology.

[16]  P. Björntorp,et al.  Effects of cortisol and growth hormone on lipolysis in human adipose tissue. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  B. Pedersen,et al.  Evidence that interleukin‐6 is produced in human skeletal muscle during prolonged running , 1998, The Journal of physiology.

[18]  J. Born,et al.  Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[20]  D. Papanicolaou,et al.  Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. , 1997, Neuroendocrinology.

[21]  M. Jensen,et al.  Lipolytic responsiveness to epinephrine in nondiabetic and diabetic humans. , 1997, The American journal of physiology.

[22]  T. van der Poll,et al.  Endocrinologic and metabolic effects of interleukin-6 in humans. , 1995, The American journal of physiology.

[23]  S. Akira,et al.  Interleukin-6 in biology and medicine. , 1993, Advances in immunology.

[24]  F. Horber,et al.  Differential Effects of Prednisone and Growth Hormone on Fuel Metabolism and Insulin Antagonism in Humans , 1991, Diabetes.

[25]  K. Alberti,et al.  Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. , 1990, The American journal of physiology.

[26]  R. Wolfe Stable isotope approaches for study of energy substrate metabolism. , 1982, Federation proceedings.

[27]  R. Steele,et al.  INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT * , 1959, Annals of the New York Academy of Sciences.